New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 28, 2014
08:23 EDTMDXGMiMedx still a top pick, says Canaccord
Canaccord reiterated its Buy rating and top pick designation for MiMedx following the company's raised guidance. The firm believes fundamentals are in place to drive execution in wound care for the foreseeable future as the company's increase in sales force remains ahead of plan and reimbursement changes support growth and increased expectations. Canaccord has a $12 price target on the stock.
News For MDXG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 18, 2014
08:06 EDTMDXGMiMedx reports abstracts to be presented at Desert Foot Conference
MiMedx Group announced that fourteen poster abstracts chronicling the company's dehydrated human amnion/chorion membrane allografts to be clinically effective and cost effective in the healing of chronic wounds, difficult lower extremity wounds that have failed prior wound treatment modalities, challenging surgical wounds, chronic neuropathic wounds, wounds threatening the loss of limbs, and other hard-to-heal wounds will be presented at the 11th Annual Desert Foot High Risk Diabetic Foot Conference in Phoenix, Arizona, beginning November 19, and concluding on November 21.
November 17, 2014
16:06 EDTMDXGMiMedx reports results of EpiFix vs. Apligraf comparative study
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use